Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease

Kidney International

Volumn 87, Issue 1, 2015, Pages 200-209

  Reinecke, Holger ^a   Nabauer, Michael ^b   Gerth, Andrea ^b   Limbourg, Tobias ^c   Treszl, Andras ^d   Engelbertz, Christiane ^a   Eckardt, Lars ^a   Kirchhof, Paulus ^a,e   Wegscheider, Karl ^d   Ravens, Ursula ^f   Meinertz, Thomas ^g   Steinbeck, Gerhard ^b   Breithardt, Günter ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Institut fur Herzinfarktforschung Ludwigshafen   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

Atrial fibrillation; Chronic kidney disease; Comorbidity; Undertreatment

Indexed keywords

ANTICOAGULANT AGENT; FLECAINIDE; SOTALOL;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PACEMAKER IMPLANTATION; PROSPECTIVE STUDY; ATRIAL FIBRILLATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY;

AGED; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920282394     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.195     Document Type: Article

References (39)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in The United States. JAMA 2007; 298: 2038-2047.
2. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in The community. J Am Coll Cardiol 2003; 41: 47-55.
3. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and The risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
4. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
5. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 209-210.
6. Ezekowitz J, McAlister FA, Humphries KH et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6, 427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592.
7. Rubenstein MH, Harrell LC, Sheynberg BV et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in The new device era? Circulation 2000; 102: 2966-2972.
8. Reinecke H, Trey T, Matzkies F et al. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 2003; 63: 696-701.
9. Szummer K, Lundman P, Jacobson SH et al. Influence of renal function on The effects of early revascularization in non-ST-elevation myocardial infarction: data from The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120: 851-858.
10. Reinecke H, Brand E, Mesters R et al. Dilemmas in The management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
11. Ananthapanyasut W, Napan S, Rudolph EH et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 173-181.
12. Winkelmayer WC, Patrick AR, Liu J et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011; 22: 349-357.
13. Vázquez E, Sánchez-Perales C, Lozano C et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92: 868-871.
14. Schäbitz WR, Reinecke H. Chronic kidney disease and alcohol consumption: are Asians at particular risk for hemorrhagic stroke? Stroke 2011; 42: 2385-2386.
15. Reinecke H, Bunzemeier H, Roeder N et al. Acute coronary syndrome in The German diagnosis-related groups system. 2: Reimbursement of interventional treatment and consequences of The current system. Med Klin (Munich) 2006; 101: 999-1001.
16. Roberts PR, Green D. Arrhythmias in chronic kidney disease. Heart 2011; 97: 766-773.
17. Nabauer M, Gerth A, Limbourg T et al. The Registry of The German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
18. Go AS, Fang MC, Udaltsova N et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369.
19. Tripepi G, Benedetto FA, Mallamaci F et al. Left atrial volume monitoring and cardiovascular risk in patients with end-stage renal disease: a prospective cohort study. J Am Soc Nephrol 2007; 18: 1316-1322.
20. Tamez H, Zoccali C, Packham D et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: e2.
21. Soliman EZ, Prineas RJ, Go AS et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107.
22. Watanabe H, Watanabe T, Sasaki S et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata preventive medicine study. Am Heart J 2009; 158: 629-636.
23. Hart RG, Pearce LA, Asinger RW et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2599-2604.
24. Imai E, Matsuo S, Makino H et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol 2010; 14: 558-570.
25. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-153.
26. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for The management of patients with atrial fibrillation: full text: a report of The American College of Cardiology/American Heart Association Task Force on practice guidelines and The European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise The 2001 guidelines for The management of patients with atrial fibrillation) developed in collaboration with The European Heart Rhythm Association and The Heart Rhythm Society. Europace 2006; 8: 651-745.
27. Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on The management of patients with atrial fibrillation (Updating The 2006 Guideline): a report of The American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2010; 8: 157-176.
28. Camm AJ, Kirchhof P, Lip GY et al. Guidelines for The management of atrial fibrillation: The Task Force for The Management of Atrial Fibrillation of The European Society of Cardiology (ESC). Europace 2010; 12: 1360-1420.
29. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
30. Wiesholzer M, Harm F, Tomasec G et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol 2001; 21: 35-39.
31. Chan KE, Lazarus JM, Thadhani R et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009; 20: 2223-2233.
32. Lai HM, Aronow WS, Kalen P et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis 2009; 2: 33-37.
33. Engelbertz C, Reinecke H. Atrial fibrillation and oral anticoagulation in chronic kidney disease. JAFIB 2012; 4: 89-100.
34. Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367: 625-635.
35. 2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 2011; 107: 912-916.
36. Naruse Y, Tada H, Sekiguchi Y et al. Concomitant chronic kidney disease increases The recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: a mid-term follow-up. Heart Rhythm 2011; 8: 335-341.
37. Schmidt M, Rieber J, Daccarett M et al. Relation of recurrence of atrial fibrillation after successful cardioversion to renal function. Am J Cardiol 2010; 105: 368-372.
38. Schmidt M, Daccarett M, Rittger H et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092-1098.
39. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.